Outcomes of percutaneous coronary interventions in patients with liver transplant.


Journal

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139

Informations de publication

Date de publication:
11 2020
Historique:
received: 07 04 2020
revised: 11 06 2020
accepted: 09 07 2020
pubmed: 30 7 2020
medline: 10 8 2021
entrez: 30 7 2020
Statut: ppublish

Résumé

Our aim is to describe characteristics of liver transplant patients undergoing percutaneous coronary interventions (PCI) as well as in-hospital outcomes including the mortality and peri-procedural complications from the largest publicly available inpatient database in the United States from 2002 to 2014. Outcomes of PCI are well studied in patients with end-stage liver disease but not well studied in patients who receive liver transplant (LT). Data derived from Nationwide Inpatient Sample (NIS) were analyzed for years 2002-2014. Adult Hospitalizations with PCI were identified using ICD-9-CM procedure codes. LT status and various complications were identified by using previously validated ICD-9-CM diagnosis codes. Endpoints were in-hospital mortality and peri-procedural complications. Propensity match analysis was performed to compare the endpoints between two groups. During the study period, 8,595,836 patients underwent PCI; 4,080 (0.04%) patients had prior LT status. 93% of patients were above age 59 years, 79% were males and 69% were nonwhites. Out of the total patients with LT status, 73% had hypertension, 57% had diabetes mellitus, and 47% had renal failure. Post-PCI complications were studied further in both liver and non-LT patients after 1:1 propensity match which showed the incidence of acute kidney injury (AKI) was higher in LT group (12.3 vs 10.7%, p = .024) but dialysis requiring AKI was similar. Among the LT recipients undergoing PCI, majority were nonwhite males. Almost more than half of the recipients had diabetes mellitus and renal failure. Incidence of AKI was higher in LT group, but other peri-procedural complications were comparable.

Sections du résumé

OBJECTIVE
Our aim is to describe characteristics of liver transplant patients undergoing percutaneous coronary interventions (PCI) as well as in-hospital outcomes including the mortality and peri-procedural complications from the largest publicly available inpatient database in the United States from 2002 to 2014.
BACKGROUND
Outcomes of PCI are well studied in patients with end-stage liver disease but not well studied in patients who receive liver transplant (LT).
METHODS
Data derived from Nationwide Inpatient Sample (NIS) were analyzed for years 2002-2014. Adult Hospitalizations with PCI were identified using ICD-9-CM procedure codes. LT status and various complications were identified by using previously validated ICD-9-CM diagnosis codes. Endpoints were in-hospital mortality and peri-procedural complications. Propensity match analysis was performed to compare the endpoints between two groups.
RESULTS
During the study period, 8,595,836 patients underwent PCI; 4,080 (0.04%) patients had prior LT status. 93% of patients were above age 59 years, 79% were males and 69% were nonwhites. Out of the total patients with LT status, 73% had hypertension, 57% had diabetes mellitus, and 47% had renal failure. Post-PCI complications were studied further in both liver and non-LT patients after 1:1 propensity match which showed the incidence of acute kidney injury (AKI) was higher in LT group (12.3 vs 10.7%, p = .024) but dialysis requiring AKI was similar.
CONCLUSION
Among the LT recipients undergoing PCI, majority were nonwhite males. Almost more than half of the recipients had diabetes mellitus and renal failure. Incidence of AKI was higher in LT group, but other peri-procedural complications were comparable.

Identifiants

pubmed: 32725872
doi: 10.1002/ccd.29168
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

E576-E584

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Mandell MS, Lindenfeld J, Tsou M-Y, Zimmerman M. Cardiac evaluation of liver transplant candidates. World J Gastroenterol. 2008;14(22):3445-3451. https://doi.org/10.3748/wjg.14.3445.
Hogan BJ, Gonsalkorala E, Heneghan MA. Evaluation of coronary artery disease in potential liver transplant recipients. Liver Transpl. 2017;23(3):386-395. https://doi.org/10.1002/lt.24679.
Azarbal B, Poommipanit P, Arbit B, et al. Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation. Liver Transpl. 2011;17(7):809-813. https://doi.org/10.1002/lt.22301.
Healthcare Cost and Utilization Project (HCUP). Overview of the National (Nationwide) Inpatient Sample (NIS). https://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed from: March 31, 2020.
Charlson ME, Ales KL, Simon R, MacKenzie CR. Why predictive indexes perform less well in validation studies. Is it magic or methods? Arch Intern Med. 1987;147(12):2155-2161.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. https://doi.org/10.1016/0021-9681(87)90171-8.
Romano PS, Geppert JJ, Davies S, Miller MR, Elixhauser A, KM MD. A national profile of patient safety in U.S. hospitals. Health Aff. 2003;22(2):154-166. https://doi.org/10.1377/hlthaff.22.2.154.
McDonald KM, Romano PS, Geppert J, et al. Measures of patient safety based on hospital administrative data-the patient safety indicators. Measures of patient safety based on hospital administrative data-the patient safety indicators. AHRQ Tech Rev. 2002. Report No.: 02-0038.
Singh V, Patel NJ, Rodriguez AP, et al. Percutaneous coronary intervention in patients with end-stage liver disease. Am J Cardiol. 2016;117(11):1729-1734. https://doi.org/10.1016/j.amjcard.2016.03.010.
Ehtisham J, Altieri M, Salamé E, Saloux E, Ollivier I, Hamon M. Coronary artery disease in orthotopic liver transplantation: pre-transplant assessment and management. Liver Transpl. 2010;16(5):550-557. https://doi.org/10.1002/lt.22035.
Bilbao I, Dopazo C, Lazaro JL, et al. Our experience in liver transplantation in patients over 65yr of age. Clin Transplant. 2008;22(1):82-88. https://doi.org/10.1111/j.1399-0012.2007.00749.x.
Zetterman RK, Belle SH, Hoofnagle JH, et al. Age and liver transplantation. Transplantation. 1998;66(4):500-506. https://doi.org/10.1097/00007890-199808270-00015.
Glauser FL. Systemic hemodynamic and cardiac function changes in patients undergoing Orthotopic liver transplantation. Chest. 1990;98(5):1210-1215. https://doi.org/10.1378/chest.98.5.1210.
Plotkin JS, Scott VL, Pinna A, Dobsch BP, De Wolf AM, Kang Y. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg. 1996;2(6):426-430. https://doi.org/10.1002/lt.500020604.
Vogt DP, Henderson JM, Carey WD, Barnes D. The long-term survival and causes of death in patients who survive at least 1 year after liver transplantation. Surgery. 2002;132(4):775-780. https://doi.org/10.1067/msy.2002.128343.
Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001;7(9):811-815. https://doi.org/10.1053/jlts.2001.27084.
Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl. 2008;14(11):1648-1654. https://doi.org/10.1002/lt.21588.
Canzanello VJ, Schwartz L, Taler SJ, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine a and tacrolimus (FK506). Liver Transpl Surg. 1997;3(1):1-9. https://doi.org/10.1002/lt.500030101.
Everhart JE, Lombardero M, Lake JR, Wiesner RH, Zetterman RK, Hoofnagle JH. Weight change and obesity after liver transplantation: incidence and risk factors. Liver Transpl Surg. 1998;4(4):285-296. https://doi.org/10.1002/lt.500040402.
Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int. 2005;18(4):461-466. https://doi.org/10.1111/j.1432-2277.2004.00067.x.
Sheiner PA, Magliocca JF, Bodian CA, et al. Long-term medical complications in patients surviving ≥5 years after liver transplant. Transplantation. 2000;69:781-789. https://doi.org/10.1097/00007890-200003150-00018.
Neal DAJ, Tom BDM, Ja L, et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant? Transplantation. 2004;77(1):93-99. https://doi.org/10.1097/01.Tp.0000100685.70064.90.

Auteurs

Harshil Shah (H)

Guthrie Healthcare System, Sayre, Pennsylvania.

Gowthami Ramineni (G)

SUNY Downstate Medical Center, Brooklyn, New York.

Rinu Varghese (R)

Sunnyvale Cardiology, Dallas, Texas.

Ei Ei Thwe (EE)

University of Medicine, Mandalay, Myanmar.

Maysar Hassan (M)

Westlake hospital, Melrose park, Illinois.

Eahab Abdul-Lattif (E)

Pontiac General Hospital, Pontiac, Michigan.

Priyal Shah (P)

The Medical Center, Navicent Health, Macon, Georgia.

Khadiza Sarker (K)

Carle Foundation Hospital, Urbana, Illinois.

Achint Patel (A)

Independent Researcher, Ahmedabad, India.

Darshan Gandhi (D)

St. Vincent's Medical Center, Bridgeport, Connecticut.

Shantanu Solanki (S)

Guthrie Healthcare System, Sayre, Pennsylvania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH